CN102232075B - 氨基吡唑化合物 - Google Patents

氨基吡唑化合物 Download PDF

Info

Publication number
CN102232075B
CN102232075B CN2009801481167A CN200980148116A CN102232075B CN 102232075 B CN102232075 B CN 102232075B CN 2009801481167 A CN2009801481167 A CN 2009801481167A CN 200980148116 A CN200980148116 A CN 200980148116A CN 102232075 B CN102232075 B CN 102232075B
Authority
CN
China
Prior art keywords
methyl
cells
chloro
imidazo
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801481167A
Other languages
English (en)
Chinese (zh)
Other versions
CN102232075A (zh
Inventor
T·P·伯克霍德尔
J·R·克莱顿
L·马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102232075(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102232075A publication Critical patent/CN102232075A/zh
Application granted granted Critical
Publication of CN102232075B publication Critical patent/CN102232075B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801481167A 2008-12-16 2009-12-08 氨基吡唑化合物 Expired - Fee Related CN102232075B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16
US61/122,854 2008-12-16
PCT/US2009/067056 WO2010074947A1 (en) 2008-12-16 2009-12-08 Amino pyrazole compound

Publications (2)

Publication Number Publication Date
CN102232075A CN102232075A (zh) 2011-11-02
CN102232075B true CN102232075B (zh) 2013-12-11

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801481167A Expired - Fee Related CN102232075B (zh) 2008-12-16 2009-12-08 氨基吡唑化合物

Country Status (38)

Country Link
US (2) US7897600B2 (https=)
EP (1) EP2379557B1 (https=)
JP (1) JP5509217B2 (https=)
KR (1) KR101300458B1 (https=)
CN (1) CN102232075B (https=)
AR (1) AR074240A1 (https=)
AU (1) AU2009330503B2 (https=)
BR (1) BRPI0923048A2 (https=)
CA (1) CA2744714C (https=)
CL (1) CL2011001445A1 (https=)
CO (1) CO6331442A2 (https=)
CR (1) CR20110341A (https=)
CY (1) CY1113637T1 (https=)
DK (1) DK2379557T3 (https=)
DO (1) DOP2011000190A (https=)
EA (1) EA019554B1 (https=)
EC (1) ECSP11011132A (https=)
ES (1) ES2396617T3 (https=)
HN (1) HN2011001697A (https=)
HR (1) HRP20120918T1 (https=)
IL (1) IL213065A0 (https=)
JO (1) JO2833B1 (https=)
MA (1) MA32900B1 (https=)
MX (1) MX2011006441A (https=)
MY (1) MY158691A (https=)
NZ (1) NZ592641A (https=)
PA (1) PA8851101A1 (https=)
PE (1) PE20110549A1 (https=)
PL (1) PL2379557T3 (https=)
PT (1) PT2379557E (https=)
SG (1) SG172202A1 (https=)
SI (1) SI2379557T1 (https=)
SV (1) SV2011003949A (https=)
TN (1) TN2011000292A1 (https=)
TW (1) TWI440640B (https=)
UA (1) UA104743C2 (https=)
WO (1) WO2010074947A1 (https=)
ZA (1) ZA201103942B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
BR112013032360A2 (pt) * 2011-06-15 2017-06-13 Life And Brain Gmbh compostos inibidores de glioblastoma e seu uso
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
EP3541817B1 (en) * 2016-11-17 2020-12-23 Bristol-Myers Squibb Company Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005673A1 (en) * 2005-07-01 2007-01-11 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
US20070083044A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20070082901A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
WO2008052734A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CN101228167A (zh) * 2005-07-21 2008-07-23 诺瓦提斯公司 作为蛋白激酶抑制剂的吡唑并[1,5-a]嘧啶-7-基-胺衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CA2467718C (en) 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2598076A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
CA2686485A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Llc Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005673A1 (en) * 2005-07-01 2007-01-11 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
CN101228167A (zh) * 2005-07-21 2008-07-23 诺瓦提斯公司 作为蛋白激酶抑制剂的吡唑并[1,5-a]嘧啶-7-基-胺衍生物
US20070083044A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20070082901A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
WO2008052734A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors;Stephanos Ioannidis et al;《Bioorganic & Medicinal Chemistry Letters》;20091024;第19卷;6524-6528 *
Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity;Steven Howard et al;《J. Med. Chem.》;20081230;第52卷;379-388 *

Also Published As

Publication number Publication date
AU2009330503A1 (en) 2010-07-01
DK2379557T3 (da) 2012-12-17
UA104743C2 (ru) 2014-03-11
AU2009330503B2 (en) 2012-06-07
CN102232075A (zh) 2011-11-02
SG172202A1 (en) 2011-07-28
TN2011000292A1 (en) 2012-12-17
HK1160109A1 (en) 2012-08-10
US20100152181A1 (en) 2010-06-17
PA8851101A1 (es) 2010-07-27
CY1113637T1 (el) 2016-06-22
MY158691A (en) 2016-10-31
US20100286139A1 (en) 2010-11-11
PL2379557T3 (pl) 2013-03-29
AR074240A1 (es) 2011-01-05
JP2012512158A (ja) 2012-05-31
ES2396617T3 (es) 2013-02-22
US7897600B2 (en) 2011-03-01
NZ592641A (en) 2013-01-25
JO2833B1 (en) 2014-09-15
TWI440640B (zh) 2014-06-11
IL213065A0 (en) 2011-07-31
JP5509217B2 (ja) 2014-06-04
BRPI0923048A2 (pt) 2018-09-25
CR20110341A (es) 2011-07-13
CA2744714C (en) 2013-06-25
ECSP11011132A (es) 2011-07-29
CL2011001445A1 (es) 2011-11-11
KR20110084993A (ko) 2011-07-26
PT2379557E (pt) 2013-01-14
KR101300458B1 (ko) 2013-08-30
MX2011006441A (es) 2011-07-19
SI2379557T1 (sl) 2013-02-28
EP2379557B1 (en) 2012-10-31
CA2744714A1 (en) 2010-07-01
ZA201103942B (en) 2012-08-29
EP2379557A1 (en) 2011-10-26
WO2010074947A1 (en) 2010-07-01
TW201024301A (en) 2010-07-01
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
HRP20120918T1 (hr) 2012-12-31
PE20110549A1 (es) 2011-08-04
EA019554B1 (ru) 2014-04-30
EA201170831A1 (ru) 2011-12-30
CO6331442A2 (es) 2011-10-20
DOP2011000190A (es) 2011-07-31
HN2011001697A (es) 2013-11-26

Similar Documents

Publication Publication Date Title
CN102232075B (zh) 氨基吡唑化合物
TWI880049B (zh) Kras g12c抑制劑
JP7337951B2 (ja) 癌を治療するための窒素含有芳香族ヘテロ環アミド誘導体
CN109776525B (zh) 作为fgfr抑制剂的双环杂环
CN108024993B (zh) 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
CN106132963B (zh) (5,6-二氢)嘧啶并[4,5-e]吲嗪
CN101981037A (zh) 吡唑并嘧啶pi3k抑制剂化合物及使用方法
CN105658652A (zh) 可用于治疗与kit相关的病症的组合物
CN103797010A (zh) 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201136939A (en) Tricyclic compounds and PBK inhibitors containing the same
WO2018038988A2 (en) Compounds, compositions, methods for treating diseases, and methods for preparing compounds
CN105050602B (zh) 作为pi3激酶抑制剂的吡啶化合物
JP7053654B2 (ja) ＰＩ３Ｋβ阻害剤としてのキノキサリン及びピリドピラジン誘導体
HK1160109B (en) Amino pyrazole compound
CN121419973A (zh) Malt1抑制剂
HK40082693B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
HK1244272B (zh) 制备噻吩并嘧啶化合物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131211

Termination date: 20161208

CF01 Termination of patent right due to non-payment of annual fee